Indaptus Therapeutics (INDP) Times Interest Earned (2020 - 2026)
Indaptus Therapeutics (INDP) posted quarterly Times Interest Earned of -$37.06 for Q1 2026, up 78.88% year-over-year from -$20.72 in Q1 2025, and up 89.09% quarter-over-quarter from -$339.82 in Q4 2025.
Indaptus Therapeutics (INDP) Times Interest Earned (2020 - 2026) Analysis & Trends
Indaptus Therapeutics' Times Interest Earned history runs 7 years deep, the most recent figure standing at -$37.06 for Q1 2026.
- In Q1 2026, Times Interest Earned rose 78.88% year-over-year to -$37.06; the TTM figure through Mar 2026 stood at -$19.14 (up 87.83% YoY), while the FY2025 annual figure was -$0.33, down 21.02% from the prior year.
- Times Interest Earned for Q1 2026 stood at -$37.06, up from -$339.82 in the prior quarter.
- The five-year high for Times Interest Earned was -$5.57 in Q2 2025, with the low at -$1079.8 in Q3 2022.
- The 5-year median for Times Interest Earned is -$37.06 (2026), against an average of -$162.09.
- The sharpest annual moves came in 2022 and 2023: Times Interest Earned sank 32765.89% in 2022, then jumped 99.29% in 2023.
- Indaptus Therapeutics' Times Interest Earned stood at -$166.98 in 2022, then advanced by 0.3% to -$166.48 in 2023, then gained by 2.9% to -$161.65 in 2024, then plunged by 110.22% to -$339.82 in 2025, then soared by 89.09% to -$37.06 in 2026.
- Business Quant data shows INDP's Times Interest Earned at -$37.06 in Q1 2026, -$339.82 in Q4 2025, and -$304.91 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.42 |
| 10 | Indaptus Therapeutics | 146.91 Mn | 135.35 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -54.10 |
| Mar 31, 2026 | -37.06 |
| Dec 31, 2025 | -339.82 |
| Sep 30, 2025 | -304.91 |
| Jun 30, 2025 | -5.57 |
| Mar 31, 2025 | -175.47 |
| Dec 31, 2024 | -161.65 |
| Sep 30, 2024 | -27.89 |
| Jun 30, 2024 | -13.27 |
| Mar 31, 2024 | -9.45 |
| Dec 31, 2023 | -166.48 |
| Sep 30, 2023 | -7.63 |
| Jun 30, 2023 | -14.66 |
| Mar 31, 2023 | -180.25 |
| Dec 31, 2022 | -166.98 |
| Sep 30, 2022 | -1,079.80 |
| Jun 30, 2022 | -29.57 |
| Mar 31, 2022 | -35.12 |
| Dec 31, 2021 | -141.00 |
| Sep 30, 2021 | -3.29 |